Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | POLE |
Variant | N363K |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | POLE N363K lies within the exonuclease domain of the Pole protein (PMID: 29352080). N363K (corresponds to N378K in yeast) results in significantly increased mutagenesis in yeast assays (PMID: 32424176), and therefore, is predicted to lead to a loss of Pole protein function. |
Associated Drug Resistance | |
Category Variants Paths |
POLE mutant POLE inact mut POLE N363K |
Transcript | NM_006231.4 |
gDNA | chr12:g.132675752G>C |
cDNA | c.1089C>G |
Protein | p.N363K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_006231.4 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
XM_011534795 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
XM_011534795.4 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
XM_011534800 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
XM_011534799 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
XM_011534799.2 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
XM_047429018.1 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
NM_006231 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
XM_011534795.3 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
NM_006231.3 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
XM_011534799.3 | chr12:g.132675752G>C | c.1089C>G | p.N363K | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
POLE N363K | endometrial cancer | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a Phase II trial, Opdivo (nivolumab) resulted in stable disease in an endometrial cancer patient harboring POLE N363K, along with high tumor mutational burden (PMID: 35398880; NCT03012581). | 35398880 |